Chastre E, Emami S, Rosselin G, Gespach C
INSERM U.55, Hôpital Saint-Antoine, Paris, France.
Endocrinology. 1987 Dec;121(6):2211-21. doi: 10.1210/endo-121-6-2211.
Changes in the functional and biochemical characteristics of membrane receptors for vasoactive intestinal peptide (VIP) were evaluated in vitro, using epithelial intestinal cells isolated during rat development, from day 17 of gestation to adulthood. These characteristics included cell cAMP generation, adenylate cyclase and cAMP-dependent phosphodiesterase cAMP-PDE activities, [125I]VIP-binding capacity, and the molecular components of [125I]VIP-binding sites. In 19-day-old fetuses, VIP induced a significant and persistent increase in cAMP production, which lasted for 10 min in intestinal cells. This effect, measured at 37 C in the absence of cAMP-PDE inhibitor, only lasted for 3 min in 5-day-old rats and was undetectable in adult intestine. Addition of the cAMP-PDE inhibitor 3-isobutyl-1-methylxanthine with VIP caused, potentiated, and maintained elevated cAMP levels at the three stages considered. Intestinal cells were more sensitive to VIP in 17- and 19-day-old fetuses (ED50 = 5 and 17 X 10(-11) M VIP, respectively, at 15 and 37 C) than in adult rats (EC50 = 2.7 and 1.6 X 10(-9) M VIP). Adenylate cyclase activity rose 4-fold in fetal intestine and had an apparent Ka of 4 X 10(-10) M VIP. These changes in VIP receptor activity were not observed for PGE2 receptors in developing rat intestinal cells or in the VIP-sensitive adenylate cyclase system prepared from liver of fetuses and adults. They might be due to differences between the molecular components of the intestinal VIP receptor, which were identified here as autoradiographic bands of 64,800 daltons in 19-day-old rat fetuses and 74,600 daltons in adults (P less than 0.01). Alternatively, the changes in VIP receptor activity in 5-day-old rats may result from decreases in the number and affinity of the [125I]VIP-binding sites and increases in the velocity of cAMP-PDE activity. The release of VIP from intestinal nerve endings during fetal and postnatal development and the absorption of VIP from milk might, therefore, modulate the intestinal VIP receptor and its effector systems. Because specific VIP receptors were expressed before the morphological and functional differentiation of intestinal and liver cells, we conclude that their activity is an indicator of their development, and suggest that in rats, this neuropeptide may regulate the maturation and functions of intestine and liver during fetal life.
利用从妊娠第17天到成年期大鼠发育过程中分离出的肠上皮细胞,在体外评估了血管活性肠肽(VIP)膜受体的功能和生化特性变化。这些特性包括细胞cAMP生成、腺苷酸环化酶和cAMP依赖性磷酸二酯酶cAMP-PDE活性、[125I]VIP结合能力以及[125I]VIP结合位点的分子成分。在19日龄胎儿的肠细胞中,VIP可诱导cAMP产生显著且持续的增加,这种增加持续10分钟。在37℃、无cAMP-PDE抑制剂的情况下测量,此效应在5日龄大鼠中仅持续3分钟,在成年肠道中则无法检测到。加入cAMP-PDE抑制剂3-异丁基-1-甲基黄嘌呤与VIP一起,在所考虑的三个阶段均使cAMP水平升高、增强并维持在较高水平。17日龄和19日龄胎儿的肠细胞对VIP比成年大鼠更敏感(在15℃和37℃时,ED50分别为5×10(-11)M和17×10(-11)M VIP,而成年大鼠的EC50为2.7×10(-9)M和1.6×10(-9)M VIP)。胎儿肠道中的腺苷酸环化酶活性增加了4倍,对VIP的表观Ka为4×10(-10)M。在发育中的大鼠肠细胞或从胎儿和成年肝脏制备的VIP敏感腺苷酸环化酶系统中,未观察到PGE2受体的这些VIP受体活性变化。它们可能是由于肠VIP受体分子成分的差异,在19日龄大鼠胎儿中鉴定为64,800道尔顿的放射自显影带,在成年大鼠中为74,600道尔顿(P<0.01)。或者,5日龄大鼠中VIP受体活性的变化可能是由于[125I]VIP结合位点数量和亲和力的降低以及cAMP-PDE活性速度的增加。因此,在胎儿和出生后发育过程中,肠神经末梢释放的VIP以及从乳汁中吸收的VIP可能会调节肠VIP受体及其效应系统。由于在肠和肝细胞的形态和功能分化之前就表达了特异性VIP受体,我们得出结论,它们的活性是其发育的指标,并表明在大鼠中,这种神经肽可能在胎儿期调节肠和肝脏的成熟及功能。